bivalirudin

This survey was conducted to better understand current United States (US) practices in terms of preferences regarding the selection of antithrombotic therapy in STEMI-PPCI, particularly in light of recent clinical trials.

This survey was conducted to...

09/01/2016

Journal of Invasive Cardiology

Update

Update: Bivalirudin in Peripheral Vascular Intervention

09/05/2008

Nicolas W. Shammas , MD, MS, FACC, FSCAI, FACP, FSVM;

Despite the sharp rise in peripheral vascular interventions (PVI), complication rates have continued to be significant and, in fact, limb loss has trended upwards.

Despite the sharp rise in...

09/05/2008

Vascular Disease Management

Original Research

Bivalirudin in Peripheral Vascular Interventions: A Single Center Experience

09/05/2008

Dawn E. McKinney , MA;

Monica Youngblut , RN;

Eric J. Dippel , MD;

Melodee Harris , RN, BSc;

Vickie S. Takes , RT(R), CCRC, RN;

Nicolas W. Shammas , MD, MS, FACC, FSCAI, FACP, FSVM;

Jon H. Lemke , PhD, MD;

Unfractionated heparin is the current antithrombotic agent utilized during peripheral angioplasty procedures.

Unfractionated heparin is the...

09/05/2008

Vascular Disease Management

Case Report

Use of Bivalirudin for Suspected Heparin-Induced Thrombocytopenia during Lower Extremity Revascularization

09/05/2008

Advantages of various direct thrombin inhibitors, a modified dosing schedule for bivalrudin, and experience with monitoring parameters are described. These advantages may form the basis for consideration when alternative anticoagulation to...

Advantages of various direct...

09/05/2008

Vascular Disease Management

Review

Current Clinical Applications of Bivalirudin: An Overview

09/05/2008

Bivalirudin is a direct thrombin inhibitor with specific and reversible actions.It is a synthetic, 20-amino acid peptide with a molecular weight of 2180 daltons. Bivalirudin directly inhibits both circulating and bound thrombin by binding to...

Bivalirudin is a direct thrombin...

09/05/2008

Vascular Disease Management